2022 年 1 并 100。委托书：The Reverse Stock Split will not change the number of authorized shares of Common Stock or preferred stock as designated by our Restated Certificate of Incorporation.8-K：The Reverse Stock Split did not affect the number of authorized shares of Common Stock or the par value of the Common Stock.反拆前（2022-09-30）：Common stock, $ 0.01 par value, 250,000,000 shares authorized; 24,729,289 and 24,710,574 shares issued and outstanding反拆后（2022-12-31）：Common stock, $ 0.01 par value, 250,000,000 shares authorized; 542,145 and 247,106 shares issued and outstanding年报附注：The par value and the authorized shares of the common and preferred stock were not adjusted as a result of the reverse stock split.

另注意：这次表决里有一股 B. Sonny Bal 以 $2,500 买下的 E 类优先股，只在反拆议案上拥有 2.5 亿票、按普通股的投票比例「镜像」投票，反拆生效即自动赎回。

2024 年 1 并 200。8-K：The reverse stock split did not affect the number of authorized shares of common stock or the par value of the common stock.反拆前（2024-03-31）：Common stock, $ 0.01 par value, 250,000,000 shares authorized; 51,080,138 and 5,320,671 shares issued and outstanding反拆后（2024-06-30）：Common stock, $ 0.01 par value, 250,000,000 shares authorized; 748,341 and 26,603 shares issued and outstanding

2019 年 1 并 30（窗口外，背景）。2019-07-12 复会的年度股东会批准 1:2–1:30（赞成 10,912,534、反对 4,566,592、弃权 348,495——赞成票只比当时在外 21,793,641 股的半数多约 15,700 股；8-K 2019-07-15），董事会定 1:30；章程修正只加一段「each thirty (30) shares … be combined and converted into one (1) share」。反拆前（2019-03-31）：Common stock, $0.01 par value, 250,000,000 shares authorized; 21,793,641 shares issued and outstanding反拆后（2019-06-30，已重述）：Common stock, $0.01 par value, 250,000,000 shares authorized; 1,854,898 shares, and 726,455 shares issued and outstanding

2017 年 1 并 12。8-K：The Reverse Stock Split will not change the authorized number of shares of common stock or preferred stock of the Company.委托书：The Reverse Stock Split will not change the number of authorized shares of Common Stock or preferred stock as designated by our Restated Certificate of Incorporation.反拆前（2017-09-30）与反拆后（2017-12-31）报表都写「250,000,000 shares authorized」；年报附注：On November 10, 2017, the Company effected a 1 for 12 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split.（8-K · Q3-17 10-Q · FY2017 10-K）

2016 年 1 并 15。委托书：The Reverse Stock Split will not change the number of authorized shares of Common Stock or preferred stock as designated by our Restated Certificate of Incorporation.Our authorized capital stock currently consists of 250,000,000 shares of Common Stock, par value $0.01, and 130,000,000 shares of preferred stock, par value $0.01.反拆前（2015-09-30，季报资产负债表只列普通股）：Common stock, $0.01 par value; 250,000,000 shares authorized; 78,936,372 and 26,353,666 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively年报附注：On January 25, 2016, the Company effected a 1 for 15 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split.反拆后（2016-03-31）：Common stock, $0.01 par value; 250,000,000 shares authorized; 11,422,636 and 10,886,248 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively（委托书 · Q3-15 10-Q · FY2015 10-K · Q1-16 10-Q）

2014 年上市前 1 并 25.7746。FY2013 年报附注：On February 11, 2014, the Company effected a 1 for 25.7746 reverse stock split of the Company’s common stock. The par value and the authorized shares of the common and convertible preferred stock were not adjusted as a result of the reverse stock split.当时授权普通股 1.5 亿、优先股 1 亿（Common stock, $0.01 par value; 150,000,000 shares authorized; 597,675 and 348,636 shares issued and outstanding at December 31, 2013 and 2012）。（FY2013 10-K · 424B4）

2014-02-19 上市重述章程——授权股唯一一次变化：The total number of shares of all classes of stock which the Corporation shall have the authority to issue is Three Hundred Eighty Million (380,000,000) shares, consisting of Two Hundred Fifty Million (250,000,000) shares of common stock, par value $0.01 per share (the “Common Stock”), and One Hundred Thirty Million (130,000,000) shares of preferred stock（重述章程 Ex.3.1）。同日 8-K 的措辞是「maintain the number of shares of authorized capital stock at 250,000,000」，但 2013 年报资产负债表写的是 1.5 亿，两者不一致；按年报与招股书资本化表，上市时授权普通股是从 1.5 亿增加到 2.5 亿、优先股从 1 亿增加到 1.3 亿。

更早：2007 年第一次申请上市时（S-1），授权为普通股 6,000 万、优先股 4,000 万，招股书写「a one-for-[ ] reverse split … to be effected immediately prior to the completion of this offering」（比例留空）；那次上市在 2007-08 撤回（RW），反拆未实施（S-1 2007 · RW 2007-08-06）。2007–2013 年之间授权如何从 6,000 万 / 4,000 万变成 1.5 亿 / 1 亿，本页没有逐份核，写作「未见一手件，待查」。

2014 年上市以来的反拆都是「只缩在外股、不缩授权股」（2016 年那次的核对见上表），2014 年上市前那次也没调整授权；这是逐次分别查到的一手件，不是从一次推另一次。授权股不是 unlimited、有面值，所以「授权 ÷ 在外」有意义：今天 250,000,000 ÷ 6,664,534 ≈ 37.5 倍。2025-01 至今没有待表决的反拆或增减授权议案，也没有 2026 年委托书。

the Company issued (i) 1,171,189 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 278,098 shares of common stock … with an exercise price of $ 0.0001 per share, and (iii) warrants to purchase 1,449,287 shares of common stock … with an exercise price of $ 3.32 per share.The Company filed a Registration Statement on Form S-3 registering the resale of the above-mentioned securities, which was declared effective by the SEC on March 27, 2025.（Q2 10-Q 附注 9；8-K；S-3）

Sinaptic Surgical agreed … to purchase 216,450 shares of the Company’s common stock at a purchase price of $3.465 per share（8-K 2025-06-27）。2025-07-10 转给 Sinaptic Holdings（13G/A）。转售登记见 S-3 2025-09-30。

被诱导行权的是 2025-02 私募附带的 $3.32 权证，其底层股已由 2025-03 的 S-3 登记转售。诱导 8-K：Immediately prior to the transactions contemplated by the Inducement Letter, the number of shares of the Company’s common stock that was issued and outstanding was 2,850,957. After giving effect to the transactions contemplated by the Inducement Letter, including the closing thereof, the number of shares of the Company’s common stock that will be issued and outstanding is 3,950,388.实际到 9/30 在外只有 3,615,856 股，差额主要是 MedTech 因 9.99% 上限被暂存的 507,254 股（8-K 2025-09-09 · Q3-25 10-Q）。新发的 1,649,147 份 $4.79 权证（及 92,392 份配售代理权证）由 S-3 2025-10-23（333-291037）申请转售登记，但截至 2026-09-18 EDGAR 上没有这份登记的 EFFECT（按数字 291037 复核，20 份 EFFECT 的正文里都没有这一号；同一方法能查到其余 19 个已生效登记号，说明不是写法造成的假空集）；2025-12-11 的 EFFECT（EFFECT）属于 Sinaptic 那份（333-290628）。所以这批权证将来行权得到的股，要么等登记生效，要么走无现金行权后按 Rule 144 计持有期——目前在价外，暂不影响现有股本。

As of June 30, 2026, 432,843 shares have been sold under the 2025 ATM Agreement for gross proceeds of $ 1.3 million, and there is $ 5.1 million capacity remaining under the 2025 ATM Agreement.（Q2 10-Q）招股补充文件的额度：$6,413,876（424B5 2025-10-03）。

买家十名（见梳理页持有人节），另有财务顾问 Arcadia Securities 与其两人 78,212 股、H.C. Wainwright 四名关联人 92,573 股配售代理权证。转售 S-3 登记 5,819,323 股，6/30 生效（S-3 · EFFECT）。

SPA 对公司的限制（SPA Ex.10.1）：From the date hereof until sixty (60) days after the Closing Date, neither the Company nor any Subsidiary shall (i) issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents in a Bona Fide Equity Financing Transaction for CashThe Company shall not enter into any Variable Rate Transaction (as defined below) during the twelve (12) month period following the Closing Date without the prior written consent of Purchasers holding a majority of the Shares issued hereunder.ATM 被明文列为豁免发行（Exempt Issuance (d)），不受这两条约束。私募条款里没有对买家的锁定期。

8-K：the Company will promptly issue to the Holder 255,267 shares of Common Stock from abeyance (the “Released Shares”) for no additional consideration, as the applicable consideration was previously paid；The issuances are intended to be exempt from registration under the Securities Act of 1933 pursuant to Section 4(a)(2) and/or Regulation D.（8-K 2026-07-02）

以下是本页的法律推算，不是申报原话。未登记的股按 Rule 144 卖：非关联人持有满 6 个月即可。行权款是 2025-09 付的（年报：Other current liabilities consisted of deposits for stock issuance of $ 1.7 million. The stock issuance is related to the 2025 Warrant Inducement），持有期从付款时起算，到 2026-06 已超过 9 个月。前提是 MedTech 不是关联人——它有 9.99% 行权上限、以 13G 被动身份申报，申报里未见它与董事高管有关联。若将来被认定为关联人，这 255,267 股（及其 MedTech 其余 400,069 股）会移到「受限量」一栏。

年报持股表（2026-03-01，FY2025 10-K）的普通股：Olson 99,553、Honigblum 204,180、Trask 35,566、Moyes 4,000、Anderson 18,000，合计 361,299；Mitchell 只有期权。另加 Lyons 8,292 股（Form 4：2/25 买 758 股、3/2 买 7,534 股；年报表中他那行 38,292 已含这 8,292 股与 30,000 份期权，但本页上面的 361,299 没有算他，不重复）Form 4，以及 Elmore 获授的 4,910 股（Form 4 代码 A，Form 4）。合计 374,501。

3/1 以后的 RSU 归属（2026-02 授予的 Olson 10 万、Honigblum 7.5 万、Trask 6 万，每半年归属 20%）未见对应的 Form 4（Honigblum 在 2025-12-05 报过一笔 RSU 交割 53,867 股，Olson 的 RSU 交割一笔都没报），所以 374,501 是下限。

2026-06 A 类（B 类同）：If, at any time during the period commencing on the Initial Exercise Date and ending on the Termination Date, the Company issues or sells shares of Common Stock or Common Stock Equivalents in a bona fide equity financing transaction for cash at a price per share less than the then-current Exercise Price of this Warrant (a “Dilutive Issuance”), then, subject to the limitations set forth below, the Exercise Price of this Warrant shall be reduced to such lower price per share. Notwithstanding the foregoing, in no event shall the Exercise Price be reduced unless and until the Company shall have obtained stockholder approval of such adjustment to the extent required by the applicable rules and regulations of The Nasdaq Stock Market LLC, including Nasdaq Listing Rule 5635(d)同一条还把 ATM 排除在外：「This Section 3(d) shall not apply to any Exempt Issuance … including, without limitation, any sales or issuances of Common Stock or Common Stock Equivalents pursuant to any “at-the-market” offering program」（Ex.4.1）。

MedTech 新权证：The exercise price is subject to full-ratchet downward adjustment in any dilutive equity financing, subject to stockholder approval to the extent required by Nasdaq Listing Rule 5635(d).（8-K 2026-07-02）

直接含义：三份都是「下一次低价现金融资 → 行权价跟着降」，ATM 卖股不触发；未经股东批准，降不到纳斯达克 Minimum Price 以下。这个下限具体是多少，原件没有写死：A/B 类写「Minimum Price (as defined in the Purchase Agreement) as of the date of issuance」，但报送的 SPA 正文里没有这个定义，按纳斯达克口径推算签约时（6/2）为 $2.14——与行权价相同，若如此则未经股东会实际降不下去；MedTech 新证写「as defined under the applicable rules and regulations of The Nasdaq Stock Market」，按 6/19 签署或 6/29 生效推算分别约 $2.11 或 $1.92，比行权价低，所以这 1,268,135 股在没有股东会时仍可能被下调到约 $1.9–$2.1。

2025-10 ATM 招股补充文件原句：Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public offering with a value exceeding more than one-third of our “public float” (i.e., the aggregate market value of our Common Stock held by our non-affiliates) in any 12 calendar-month period so long as our public float remains below $75.0 million.（424B5）

这是为什么「ATM 剩余 $510 万」不能直接当成可卖额度：在现价下，货架规则把它压到大约一半。股价上涨会同时抬高上限。

本窗口（8/20–9/17）最大单日只占 10.4%，三档分母差不到 6%，所以三档天数接近。但如果窗口往前挪到 8/11–9/8（同样 20 个交易日），8/11 一天就占 76.3%：

同一批股，含极值均量会把「约 250 天」说成「25 天」，差约 10 倍；即便剔掉 8/11，8/12、8/13 两天各 30 万股的量仍把剔极值均量抬高到 6.2 万。这就是三档都要给、并写明窗口的原因。8/11 那笔量的核对见 梳理页 8/11 小节：它不在分时里、不在 FINRA 场外报告里，也不对应任何发股。

所以对 SINT，「翻倍」不是一个日期，而是一个价格：大约在股价回到 $2.14 以上、并且权证持有人愿意行权之后。9.99% 上限会让这个过程分批进行，而不是一天完成。